Current Trends and Future Perspectives in the Treatment of Pulmonary Hypertension: WHO Group II-V

Sukhdeep Bhogal; Debabrata Mukherjee; Subhash Banerjee; AKM Monwarul Islam; Ramesh Daggubati; Timir K. Paul

doi:10.1016/j.cpcardiol.2017.10.003

Current Trends and Future Perspectives in the Treatment of Pulmonary Hypertension: WHO Group II-V

Sukhdeep Bhogal, Debabrata Mukherjee, Subhash Banerjee, AKM Monwarul Islam, Ramesh Daggubati, Timir K. Paul

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Pulmonary hypertension continues to be a life-threatening illness with debilitating physical and emotional consequences affecting around 1% of global population. The progression of this devastating disease is characterized by increase in pulmonary vascular resistance resulting in elevated pulmonary pressure, eventually leading to right heart failure and death. Better understanding of pathophysiology has led to substantial improvements in terms of availability of treatment options. The purpose of this review is to summarize the currently available treatment options along with pertinent trials and possible future therapies of pulmonary hypertension group II-V.

Original language	English (US)
Pages (from-to)	217-231
Number of pages	15
Journal	Current Problems in Cardiology
Volume	43
Issue number	5
DOIs	https://doi.org/10.1016/j.cpcardiol.2017.10.003
State	Published - May 2018

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.cpcardiol.2017.10.003

Cite this

@article{b2d96202bb304f1f81fe2ab577c09ed3,

title = "Current Trends and Future Perspectives in the Treatment of Pulmonary Hypertension: WHO Group II-V",

abstract = "Pulmonary hypertension continues to be a life-threatening illness with debilitating physical and emotional consequences affecting around 1% of global population. The progression of this devastating disease is characterized by increase in pulmonary vascular resistance resulting in elevated pulmonary pressure, eventually leading to right heart failure and death. Better understanding of pathophysiology has led to substantial improvements in terms of availability of treatment options. The purpose of this review is to summarize the currently available treatment options along with pertinent trials and possible future therapies of pulmonary hypertension group II-V.",

author = "Sukhdeep Bhogal and Debabrata Mukherjee and Subhash Banerjee and Islam, {AKM Monwarul} and Ramesh Daggubati and Paul, {Timir K.}",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier B.V.",

year = "2018",

month = may,

doi = "10.1016/j.cpcardiol.2017.10.003",

language = "English (US)",

volume = "43",

pages = "217--231",

journal = "Current Problems in Cardiology",

issn = "0146-2806",

publisher = "Mosby Inc.",

number = "5",

}

TY - JOUR

T1 - Current Trends and Future Perspectives in the Treatment of Pulmonary Hypertension

T2 - WHO Group II-V

AU - Bhogal, Sukhdeep

AU - Mukherjee, Debabrata

AU - Banerjee, Subhash

AU - Islam, AKM Monwarul

AU - Daggubati, Ramesh

AU - Paul, Timir K.

PY - 2018/5

Y1 - 2018/5

N2 - Pulmonary hypertension continues to be a life-threatening illness with debilitating physical and emotional consequences affecting around 1% of global population. The progression of this devastating disease is characterized by increase in pulmonary vascular resistance resulting in elevated pulmonary pressure, eventually leading to right heart failure and death. Better understanding of pathophysiology has led to substantial improvements in terms of availability of treatment options. The purpose of this review is to summarize the currently available treatment options along with pertinent trials and possible future therapies of pulmonary hypertension group II-V.

AB - Pulmonary hypertension continues to be a life-threatening illness with debilitating physical and emotional consequences affecting around 1% of global population. The progression of this devastating disease is characterized by increase in pulmonary vascular resistance resulting in elevated pulmonary pressure, eventually leading to right heart failure and death. Better understanding of pathophysiology has led to substantial improvements in terms of availability of treatment options. The purpose of this review is to summarize the currently available treatment options along with pertinent trials and possible future therapies of pulmonary hypertension group II-V.

UR - http://www.scopus.com/inward/record.url?scp=85034431440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034431440&partnerID=8YFLogxK

U2 - 10.1016/j.cpcardiol.2017.10.003

DO - 10.1016/j.cpcardiol.2017.10.003

M3 - Article

C2 - 29153390

AN - SCOPUS:85034431440

SN - 0146-2806

VL - 43

SP - 217

EP - 231

JO - Current Problems in Cardiology

JF - Current Problems in Cardiology

IS - 5

ER -

Current Trends and Future Perspectives in the Treatment of Pulmonary Hypertension: WHO Group II-V

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this